Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Mepolizumab effectiveness and identification of super-responders in severe asthma

Open access
Harvey, Erin S., Langton, David, Katelaris, Constance, Stevens, Sean, Farah, Claude S., Gillman, Andrew, Harrington, John, Hew, Mark, Kritikos, Vicky, Radhakrishna, Naghmeh, Bardin, Philip, Peters, Matthew, Reynolds, Paul N., Upham, John W., Baraket, Melissa, Bowler, Simon, Bowden, Jeffrey, Chien, Jimmy, Chung, Li Ping, Grainge, Christopher, Jenkins, Christine, Katsoulotos, Gregory P., Lee, Joy, McDonald, Vanessa M., Reddel, Helen K., Rimmer, Janet, Wark, Peter A.B., Gibson, Peter G. · 2020 · European Respiratory Journal

Abstract

Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population. The Australian Mepolizumab Registry (AMR) was established with an aim to assess the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia. Patients (n=309) with severe eosinophilic asthma (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control (median Asthma Control Questionnaire (ACQ)-5 score of 3.4), frequent exacerbations (median three courses of oral corticosteroids (OCS) in the previous 12 months), and 47% required daily OCS. Median baseline peripheral blood eosinophil level was 590 cells·µL−1. Comorbidities were common: allergic rhinitis 63%, gastro-oesophageal reflux disease 52%, obesity 46%, nasal polyps 34%. Mepolizumab treatment reduced exacerbations requiring OCS compared with the previous year (annualised rate ratio 0.34 (95% CI 0.29–0.41); p<0.001) and hospitalisations (rate ratio 0.46 (95% CI 0.33–0.63); p<0.001). Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline. Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.02420-2019

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 190

Metadata

Authors
Harvey, E. S., Langton, D., Katelaris, C., Stevens, S., Farah, C. S., Gillman, A., Harrington, J., Hew, M., Kritikos, V., Radhakrishna, N., Bardin, P., Peters, M., Reynolds, P. N., Upham, J. W., Baraket, M., Bowler, S., Bowden, J., Chien, J., Chung, L. P., Grainge, C., Jenkins, C., Katsoulotos, G. P., Lee, J., McDonald, V. M., Reddel, H. K., Rimmer, J., Wark, P. A. B., & Gibson, P. G.
Venue
European Respiratory Journal
Published
2020-03-05
Volume
55
Issue
5
Pages
1902420
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W3009509122
Cited by
190
References
3
FWCI
16.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mepolizumab effectiveness and identification of super-responders in severe asthma. https://app.cochat.ai/papers/10.1183/13993003.02420-2019
The paper
Harvey, E. S., Langton, D., Katelaris, C., Stevens, S., Farah, C. S., Gillman, A., Harrington, J., Hew, M., Kritikos, V., Radhakrishna, N., Bardin, P., Peters, M., Reynolds, P. N., Upham, J. W., Baraket, M., Bowler, S., Bowden, J., Chien, J., Chung, L. P., . . . Gibson, P. G. (2020). Mepolizumab effectiveness and identification of super-responders in severe asthma. European Respiratory Journal. https://doi.org/10.1183/13993003.02420-2019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.